{"id":"placebo-anacetrapib","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Back pain"},{"rate":"5-10%","effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL1800807","moleculeType":"Small molecule","molecularWeight":"637.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CETP, anacetrapib increases the levels of high-density lipoprotein (HDL) cholesterol and decreases the levels of low-density lipoprotein (LDL) cholesterol. This mechanism is thought to reduce the risk of cardiovascular events.","oneSentence":"Anacetrapib is a cholesterol ester transfer protein (CETP) inhibitor, which increases HDL cholesterol and reduces LDL cholesterol.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:33.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of cardiovascular events in patients with atherosclerotic cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT01252953","phase":"PHASE3","title":"REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2011-06","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":30449},{"nctId":"NCT02931188","phase":"","title":"The Effect of Anacetrapib on Vascular Function and Arterial Stiffness","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-01","conditions":"Atherosclerotic Cardiovascular Disease, Vascular Disease","enrollment":103},{"nctId":"NCT01860729","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05-13","conditions":"Hypercholesterolemia","enrollment":589},{"nctId":"NCT01524289","phase":"PHASE3","title":"Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-03","conditions":"Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial","enrollment":306},{"nctId":"NCT00685776","phase":"PHASE3","title":"Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03-24","conditions":"Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease","enrollment":1623},{"nctId":"NCT01760460","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-03-14","conditions":"Dyslipidemia","enrollment":307},{"nctId":"NCT01717300","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-06","conditions":"Hypercholesterolemia","enrollment":459},{"nctId":"NCT01824238","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":68},{"nctId":"NCT00990808","phase":"PHASE1","title":"The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Dyslipidemia","enrollment":46},{"nctId":"NCT01841684","phase":"PHASE3","title":"Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06","conditions":"Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia","enrollment":2},{"nctId":"NCT00977288","phase":"PHASE2","title":"A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Dyslipidemia","enrollment":408},{"nctId":"NCT00325455","phase":"PHASE2","title":"MK0859 Dose-Ranging Study (0859-003)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Hypercholesterolemia, Mixed Hyperlipemia","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo anacetrapib","genericName":"Placebo anacetrapib","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anacetrapib is a cholesterol ester transfer protein (CETP) inhibitor, which increases HDL cholesterol and reduces LDL cholesterol. Used for Reduction of cardiovascular events in patients with atherosclerotic cardiovascular disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}